Radiological staging in pregnant patients with cancer. by Woitek, Ramona et al.
Radiological staging in pregnant
patients with cancer
Ramona Woitek, Daniela Prayer, Azadeh Hojreh, Thomas Helbich
To cite: Woitek R, Prayer D,
Hojreh A, et al. Radiological
staging in pregnant patients
with cancer. ESMO Open
2016;1:e000017.
doi:10.1136/esmoopen-2015-
000017
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
esmoopen-2015-000017).
Received 11 January 2016
Accepted 13 January 2016
Department of Biomedical
Imaging and Image-guided
Therapy, Medical University
of Vienna, Vienna, Austria
Correspondence to
Dr Ramona Woitek; ramona.
woitek@meduniwien.ac.at
INTRODUCTION
Malignant diseases during pregnancy are rela-
tively rare, with an estimated incidence of 1 in
1000 pregnancies.1 Owing to an increasing
delay of pregnancy to the third and fourth
decades of life, cancer will occur increasingly
more frequently during pregnancy. Diagnosis
is reportedly often delayed during pregnancy,
due to overlapping symptoms of pregnancy
and malignant disease, leading to higher
stages of disease at diagnosis.1
After a malignant tumour is diagnosed
during pregnancy, the pregnant patients with
cancer must be provided with diagnostic
imaging for the evaluation of disease extent,
and to allow the same high-quality therapy
planning as that received by a non-pregnant
patient. At the same time, it is of the utmost
importance to limit harm to the fetus from
diagnostics and therapeutics as much as pos-
sible. Diagnostic imaging for staging purposes
relies, to a large extent, on ionising radiation
used in CT and in nuclear imaging modal-
ities, as well as on the intravenous application
of contrast agents. These methods cannot be
recommended outright during pregnancy,
due to possible detrimental effects on the
fetus. In the pregnant patient, the attending
physician is challenged with the choice of
diagnostic imaging modalities, while limiting
danger to the fetus as much as possible, and
still enabling disease management similar to
that in a non-pregnant patient. Therefore,
malignant disease in pregnant patients
should be managed by a multidisciplinary
tumour board that has the competence to
evaluate different strategies for staging,
including invasive and non-invasive methods.
In this article, the challenging task of finding
appropriate imaging modalities for the
staging of different malignant tumours that
occur during pregnancy will be discussed.
IONISING RADIATION
Proliferating cells are more sensitive to radi-
ation effects than cells that have completed cell
division.2 The human embryo or fetus is a
rapidly proliferating organism and, therefore,
especially sensitive to radiation effects.
Potential adverse effects from prenatal radi-
ation due to imaging may comprise spontan-
eous abortion, congenital malformations
(teratogenesis) and carcinogenesis (table 1).2–4
To evaluate the risk the fetus undergoes
due to imaging of the pregnant patient, the
range of radiation dose that is applied
during the most common imaging studies
must be considered (table 2).
Spontaneous abortion
Radiation exposure over 50–100 mGy during
the first 2 weeks after conception and before
implantation results in either spontaneous
abortion or a completely unaffected embryo
(‘all-or-none effect’).4–6 The likelihood of
inducing abortion at doses below 50 mGy is
low and supposedly not distinguishable from
zero.6 7 It is noteworthy that the average risk
of spontaneous abortion is approximately
15% without any additional ionising radi-
ation due to imaging.7
Teratogenesis
Teratogenesis is a non-stochastic or determin-
istic effect of radiation, for which a threshold
exists, estimated to be around 50–100 mGy.
Above this threshold, cellular repair mechan-
isms fail, leading to loss of tissue function.
The severity of this effect increases with
dose.2 4 6 8 During organogenesis (between 3
and 8 weeks of gestation) and during the
early fetal period (until the 15th week of ges-
tation), when rapid neuronal development
and migration take place, the fetus is most
susceptible to the teratogenic effects of radi-
ation.4 6 7 Radiation exposure above 100 mGy
during that time may lead to mental retard-
ation, microcephaly and intrauterine growth
restriction.2 4 6 After 16 weeks of gestation,
the threshold for teratogenic effects is around
500–700 mGy.7 Outside this time window, and
especially after 26 weeks of gestation, terato-
genic effects are extremely unlikely at dose
levels reached in diagnostic radiology.9 10
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The risk for radiation-induced mental retardation is
highest from the 8th to the 15th week.2 During this
time, the average IQ reduction is approximately 2.5–3.1
IQ-points per 100 mGy above a threshold of
100 mGy.2 11
Intrauterine growth retardation after fetal irradiation
above the same threshold does occur, but is usually tran-
sient, meaning that the fetus is able to recover with
time.7
Furthermore, the probability of a fetus not developing
any malformation is 96%. This probability is still 95.9%
after a fetal dose of 50 mGy, and 95.8% after
100 mGy.6 12 The fetal dose usually does not exceed
50 mGy in a single radiological imaging study. The
American College of Obstetricians and Gynecologists
has even stated that exposure to <50 mGy has not been
associated with an increase in fetal anomalies or preg-
nancy loss at all.13 Therefore, carcinogenesis is often the
radiation effect that should concern radiologists and
treating physicians more than teratogenesis.
Carcinogenesis
Carcinogenesis is a stochastic effect of radiation that
does not result in a loss of tissue function, but does
result in DNA mutations. Carcinogenic effects can occur
at any dose and do not require any dose threshold. The
probability of the effect to occur increases linearly with
dose.2 After an abdominal CT with a maximum uterine
dose of 50 mGy, the relative risk of childhood malignan-
cies may approximately double.14–16 More specifically,
carcinogenic risk varies according to the trimester in
which radiation exposure happens. It is assumed to be
highest after radiation exposure during the first trimes-
ter of pregnancy, with the relative risk for childhood
cancer from the same dose of ionising radiation esti-
mated to be 3.19 in the first trimester, and around 1.3 in
the second and third trimesters, when organogenesis
has been completed.2 4 17 But, it is important to remem-
ber that the baseline cumulative risk of childhood
cancer without any kind of diagnostic imaging during
pregnancy is very low, at 1–2.5 per 1000 until the age of
15 years.4 18 Therefore, after intrauterine radiation
exposure of 50 mGy, even 1.3–3.19 times this incidence
rate could still be considered a low risk for childhood
cancer.
Termination of pregnancy
Because of the quite minor risk of teratogenesis or car-
cinogenesis after radiation doses of up to 100 mGy,
Table 1 Overview of potential adverse effects resulting from prenatal exposure to ionising radiation
Effect
Most sensitive
period after
conception (d)
Threshold dose at which
an effect was observed
(mGy)
Absolute
incidence
(%/mGy) Comment
Prenatal death 0–8 100 0.1 If the conceptus survives, it is
thought to develop fully, without
radiation damage
Growth
retardation
8–56 200 NA
Organ
malformation
14–56 100 0.05
Small head size 14–105 NA 0.05–0.10 Mental retardation in 25% of
children with small head size
Severe mental
retardation
56–105 100 0.01–0.04
Reduction of IQ 56–105 100 0.01–0.03
Childhood
cancer
0–77 − 0.017 Most commonly leukaemia
Inheritable
damage
0.0003 in males
0.0001 in
females
Modified after references6 10 and81.
NA, not applicable.
Table 2 Ranges of radiation dose applied during the
most common imaging studies
Imaging
Typical fetal
radiation
dose (mGy)
Chest radiograph <0.01
Mammography (2 planes, bilateral) <0.01
CT of the head <0.005–0.5
CT of the chest 0.01–0.66
CT of the abdomen/pelvis 8–25
99mTc bone scintigram 3.3
18F-FDG PET 1.1–9.04
Modified after references1 7 52 and82.
18F-FDG PET, 18F fluorodeoxyglucose positron emission
tomography.
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termination of pregnancy would not be justified. Above
200–500 mGy, the decision to abort a fetus has to be
made based on individual circumstances, such as the
requirement for serial-cross sectional imaging studies,
interventions or radiation therapy.4 Above 500 mGy, clin-
ically significant fetal damage may result from diagnostic
imaging, such as significant mental radiation after radi-
ation exposure during the 7th–25th weeks of gestation.
Therefore, termination of pregnancy may be recom-
mended in this setting.4 6 19
IMAGING MODALITIES
When choosing an appropriate imaging modality to
evaluate the local extent or distant spread of a malig-
nant lesion during pregnancy, the following issues
should be considered: (1) safety of the fetus; (2) prob-
ability of metastatic disease and (3) the ability to achieve
a staging accuracy similar to that in a non-pregnant
patient.4 Non-ionising imaging modalities, such as ultra-
sound (US) and MRI, are preferable when equivalent in
accuracy to imaging that involves ionising radiation.
When ionising radiation is used for imaging, the cumu-
lative uterine dose should be kept as low as reasonably
achievable (ALARA).4
Projection radiography
If the fetus is not directly within the region to be exam-
ined, fetal radiation exposure is generally negligible and
pregnancy should not alter the decision to perform an
indicated examination.4 Generally, projection radiog-
raphy has only limited sensitivity in the detection of
metastatic disease. The radiologist should be aware that,
after a chest radiograph with either positive or negative
findings concerning metastatic disease, further imaging
of the chest may be warranted. If the probability is low
that projection radiography would definitely answer a
clinical question, MRI (preferably without contrast) or
CT (if it does not directly involve the fetus) should be
considered.
CT
The fetal dose in CT scans of the maternal head, neck
and extremities results from scatter radiation, and is neg-
ligible. The dose increases tremendously when the fetus
is in the field of view.8 Technicians and radiologists
exposing the pregnant patient and the fetus to ionising
radiation are especially obliged to adhere to the princi-
ples of keeping the radiation dose as low as reasonably
achievable (ALARA). To achieve the lowest reasonably
possible dose that still would allow accurate image
quality, technicians and radiologists should adjust the
following parameters: tube potential (kV) may be
lowered based on the patient’s body weight; the tube
current-time product (mAs) may be decreased; the
pitch may be increased above 1; the number of acquisi-
tions may be limited to one; automated exposure
control, automatic tube current modulation and iterative
reconstruction, may be used.4 6 20 21 Caution is war-
ranted when decreasing radiation dose during CT.
Situations should be avoided in which diagnostic accur-
acy is diminished due to low image quality and examina-
tions involving ionising radiation might then have to be
repeated.
Abdominal shielding during any CT does not result in
substantial dose reduction, because most of the fetal
dose results from internal scatter radiation rather than
from direct radiation. Alternatively, internal shielding
using oral barium in suspensions beyond 30% does
reduce the fetal radiation dose.22
Iodinated contrast agents
A single layer of chorionic epithelium serves as an inter-
face between the maternal and fetal circulation in the
placenta. Iodine-based contrast agents are limited in
their ability to cross the placenta, due to their relatively
high molecular weights.23 Nevertheless, measurable
amounts of iodinated contrast agents were detected in
the fetus after intravenous administration of typical clin-
ical doses to the mother.24 After the iodinated contrast
agent transverses the placenta and enters the fetal blood
stream, it is excreted by the fetal kidneys and reaches
the amniotic fluid via fetal urine. The fetus swallows
amniotic fluid continuously, which lets the contrast
enter the fetal gut. Alternative routes from maternal
blood into the amniotic fluid have also been
suggested.23 25
It is recommended that an iodinated contrast agent
be used if the expected information could affect treat-
ment during pregnancy and if it is unjustifiable to delay
the examination until after pregnancy.4 24 26 In vivo tests
in animals did not reveal any mutagenic or teratogenic
effects. But, to date, well-controlled studies of the terato-
genic effects in pregnant women have not been per-
formed.24 Fetal thyroid gland function is essential for
the development of the central nervous system. Postnatal
hypothyroidism has rarely been reported after the injec-
tion of high doses of fat-soluble iodinated contrast
agents. Conversely, an intravenously administered low-
osmolarity, water-soluble iodinated contrast agent does
not have short-term effects on thyroid function in the
newborn, probably because the overall amount of excess
iodide in the fetal circulation is small and transient.24
However, long-term effects are still unknown. To date,
no single case of neonatal hypothyroidism from mater-
nal intravascular injection of water-soluble iodinated
contrast agents has been documented.26 27 Newborns
are now routinely evaluated for hypothyroidism during
the first week of life. If this screening is performed, no
extra attention is felt to be necessary for cases of intra-
venous administration of iodinated, water-soluble con-
trast agents at routine clinical doses during
pregnancy.24 28 29 In countries without routine screening
for hypothyroidism, an extra test should be performed
during the first week of life if an iodinated contrast
agent was administered to the mother during pregnancy.
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A general rule for the imaging strategy in a pregnant
patient is to intravenously administer the iodinated con-
trast agent for an examination that would also be per-
formed with contrast agent if the patient was not
pregnant. Otherwise, it might be necessary to repeat the
examination because of imaging limitations due to the
lack of contrast.4 8
Mammography
When abdominal shielding is used, mammography does
not present a risk to the fetus.30 31 If, after initial breast
ultrasound (US), mammography is needed, it should
start with one mediolateral-oblique view. In case of a sus-
picious mass, craniolateral and mediolateral-oblique
views of both breasts are usually acquired to evaluate the
patient for widespread suspicious microcalcifications,
multicentric and bilateral disease.30
Ultrasound
US is frequently the first-line imaging tool for the evalu-
ation of the fetus and mother. US is generally consid-
ered a safe imaging modality, but should nevertheless be
performed only when indicated.32 Energy deposition by
US exposure and subsequent tissue heating with haem-
orrhage or cavitation should be limited. The examiner
should adhere to the ALARA principle, although no
teratogenic effects from US have been found in humans
thus far.33 The US examination should be limited to
30 min; Doppler US should not be routinely used in
early pregnancy, due to higher energy deposition in the
body tissues.4 33
MRI
To date, MRI during pregnancy has not been shown to
have any adverse effects on the fetus. Nevertheless, the
safety of MRI during pregnancy needs to be further
investigated.34 Unlike with CT, the potential fetal risks
due to MRI are predominantly teratogenic, not carcino-
genic.34 The potential teratogenic effects of MRI result
from the static magnetic field, which can potentially
alter cell migration, proliferation and differentiation.34 35
The majority of studies supporting the potential terato-
genic effects of MRI have been performed in animals
and have reported controversial results.36 Studies per-
formed in humans have not found adverse effects from
MRI for as much as 9 years after the exposure of the
fetus.37–39 Generally, MRI is to be preferred over ionising
radiation, whenever possible.4 In 2013, the American
College of Radiology stated that MRI can be used in
pregnant patients regardless of gestational age when the
results are likely to influence treatment and cannot be
obtained by other non-ionising means, and when MRI
cannot be postponed until after gestation.35 There are
still no data about the risks of exposure during the first
trimester; therefore, it may still be sensible to avoid
unnecessary scanning during this period. The fetus is
more susceptible to teratogenic effects during this devel-
opmental phase and heat loss may be more
compromised during the first trimester, because placen-
tal blood flow is not yet properly established.40 The static
magnetic field, the time-varying magnetic field gradients
and radiofrequency pulses, may potentially harm the
fetus.34 35
Radiofrequency pulses deposit energy within body
tissues, potentially increasing body temperature. This
energy deposition is measured as the specific absorption
rate (SAR) in watts per kilogram (W/kg). An increase in
temperature has been shown to cause malformations in
animals34 41 42 and teratogenic effects have also been
postulated for humans in cases where the maternal tem-
perature increase is >2–2.5°C for 30–60 min.4 36
Controversial estimations have been published concern-
ing a potential increase in fetal body temperature
during MRI. In case of a maternal whole-body exposure
of 2 W/kg for a duration of 7.5 min, the fetal body tem-
perature may increase by >1°C. Therefore, it would not
be recommended to scan pregnant patients above the
normal whole-body SAR level of 2 W/kg.40 Thus, it is
recommended that MRI protocols be designed in such a
way that higher SAR sequences (ie, HASTE/SSFSE) and
lower SAR sequences are interleaved.40 Furthermore, it
is recommended that pregnant patients be imaged at
field strengths of no more than 3 T, to keep the SAR
low.34 43 44
In animals, it has been postulated that electromag-
netic fields may alter cell migration, proliferation and
differentiation.45 In humans, thus far, no detrimental
effects have been shown. Nevertheless, it is recom-
mended that the only MR examinations that should be
performed are those that are considered necessary
during pregnancy, and to postpone any elective MRI
until after gestation.4
Rapid gradient switching causes considerable noise
during MRI. Up to 80–120 dB may be produced during
an MRI protocol at 3 T, noise that has been reported to
cause temporary hearing loss in those patients exam-
ined.4 46 Therefore, the use of headphones or earplugs
or both has become common practice to protect
patients from hearing loss. Above 90 dB, the fetal ear
may also be permanently damaged, especially after
34 weeks of gestation, when the fetal ear is developed.4 34
The maternal body attenuates at least 30 dB. If MRI pro-
duces 120 dB, 90 dB could still reach the fetal ear and
put it at risk for substantial damage.4 34 Therefore,
sequences that cause loud noise, such as fast gradient
echo sequences, should be kept as short as possible.4 To
date, no association of prenatal MRI and postnatal
hearing impairment has been observed.39
Gadolinium-based contrast agent
In animals, gadolinium has been shown to have terato-
genic effects when administered in high doses.47 To date,
no adverse event effects on the human fetus when
gadolinium-based contrast agents were administered at
clinically recommended doses during pregnancy have
been documented.4 23 48 In a single-cohort study of 26
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women, exposure to gadolinium chelates during the first
trimester showed neither teratogenic nor mutagenic
effects on the fetus.24 49 But, to date, no controlled studies
of teratogenic effects have been undertaken, and it is not
clear how gadolinium affects the fetus. Therefore, during
pregnancy and especially organogenesis, gadolinium
should be administered only if there is an absolutely essen-
tial clinical indication, if the potential benefits justify the
unknown potential fetal risk and if there is no alternative,
such as contrast-enhanced CT, to address the clinical ques-
tion.4 16 24 Gadolinium crosses the placenta and, after
renal excretion, may accumulate in the amniotic fluid.
Subsequent dissociation of the toxic, free gadolinium ion
is possible, which could carry a risk for the development of
nephrogenic systemic fibrosis (NSF) in the mother and
the child.24 Therefore, a gadolinium-based contrast agent
that is associated with a low risk for developing NSF (gado-
butrol (Gadovist), gadoteridol (Prohance), gadoterate
meglumine (Dotarem))—at the lowest possible dose—
should be used.24 50
Positron emission tomography and scintigraphy
In PET and scintigraphy, the fetus is exposed to ionising
radiation by the radioactive tracer that accumulates in
maternal body tissues and organs, then crossing the pla-
centa to enter the fetal circulation.51 Typically, the tracer
dose is reduced, to minimise fetal exposure, with a com-
pensatory increase in image acquisition time.51 During
18F fluorodeoxyglucose positron emission tomography
(18F-FDG PET), the fetus is exposed to doses of approxi-
mately 0.00616–0.0305 mGy/MBq, with the overall fetal
dose usually below 10 mGy (table 2).52
In scintigraphic imaging during pregnancy, the most
common isotope in use is 99mTc, as is used for bone scin-
tigraphy. During this examination, the fetus is exposed
to a radiation dose of <5 mGy.4 51 For thyroid gland scin-
tigraphy during pregnancy, 123I or 99mTc are recom-
mended tracers, because of their short half-life.4 13
For tracers that are excreted renally, adequate hydra-
tion, intravenous application of 20 mg of furosemide
15 min after tracer application and bladder catheterisa-
tion are recommended, to minimise fetal radiation.51
While PET and scintigraphy alone cause only minor
radiation exposure of the fetus, PET/CT exposes the
fetus to a relatively high radiation dose due to the com-
bination of two imaging methods involving ionising radi-
ation. Therefore, PET/CT should be postponed until
after completion of pregnancy.1 53 PET/MRI is a reason-
able alternative to eliminate the ionising radiation from
CT, which could be considered for the staging of lymph-
oma, for example.54
IMAGING OF METASTATIC SPREAD TO SPECIFIC REGIONS
OF THE BODY
Metastatic pulmonary nodules
Pulmonary metastases can be evaluated with chest radio-
graphs, CT or with dedicated MRI. CT offers the highest
sensitivity, with only minor radiation exposure of the
fetus (table 2).55 56 Chest radiographs in the posteroan-
terior and lateral views may generally be accepted as
screening tools in non-pregnant patients with known
malignant disease, but with a low clinical suspicion of
metastatic disease.57 Chest CT is much more sensitive
for the detection of pulmonary metastases, due to the
higher spatial resolution and lack of superimposition of
anatomical structures. In case of clinical suspicion of
pulmonary metastases or a high propensity of the under-
lying malignancy for metastatic spread to the lungs, as is
the case in sarcomas, head and neck cancer, and
advanced stage melanoma, CT of the chest is indicated
in the non-pregnant patient.57 The same indications for
radiological screening for pulmonary metastases should
be applied to pregnant patients. Chest radiography and
chest CT without contrast only result in minimal radi-
ation exposure of the fetus (table 2), while the finding
of pulmonary metastases as a sign of disease spread may
tremendously affect treatment. Increasing numbers of
studies exist that report MRI of the chest to perform
similarly to CT in the detection of pulmonary metasta-
ses, thus supporting an increasing role of MRI; this
needs to be further evaluated.58–62 MRI should only be
used for the detection of pulmonary metastases if the
radiologist and technician are experienced in the appli-
cation of MRI for this indication, otherwise, CT of the
chest may be considered.
Metastatic mediastinal lymphadenopathy
To evaluate mediastinal lymph nodes for metastatic
disease, MRI has been shown to be comparable to CT.63
If a patient needs imaging of the chest to evaluate for
pulmonary metastases and there is a reasonable chance
of having mediastinal metastatic lymph adenopathy,
chest CT acquired after the intravenous application of
iodinated contrast agent appears to be a reasonable
imaging strategy to allow assessment of the lung paren-
chyma and an optimised evaluation of mediastinal struc-
tures at the same time. After administration of an
iodinated contrast agent during pregnancy, screening of
the newborn for hypothyroidism is warranted, as men-
tioned above.
Bone metastases
To scan for distant metastases in the bones, MRI that
includes T1-weighted sequences, short τ inversion recovery
sequences and diffusion-weighted imaging is the primary
imaging method of choice during pregnancy.64–67 Bone
scintigraphy during pregnancy is recommended only if
MRI cannot be performed or cannot sufficiently answer
the question of whether skeletal metastases are present.
Brain metastases
To scan for brain metastases in patients with neuro-
logical symptoms, MRI without contrast agent is the pre-
ferred imaging modality.56
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STAGING OF DIFFERENT MALIGNANT DISEASES
Cancer during pregnancy is a relatively rare phenom-
enon, with an incidence of 1 in 1000–1500 pregnan-
cies.68 Diagnosis and treatment should be optimised
towards the maximal benefit for the mother while avoid-
ing harm to the child as much as possible. The inci-
dence of malignancies in pregnant women is similar to
that in non-pregnant women of the same age.1 The
most frequently diagnosed malignancies are listed in
table 3.
Breast cancer
Breast US with reported high sensitivity and specificity is
the standard method for the evaluation of a palpable
breast lesion during pregnancy.30 Breast US allows a con-
fident diagnosis of clearly benign lesions, such as simple
cysts. After identifying a solid lesion, controversial
recommendations have been reported concerning
further work up. Biopsy is warranted without delay,56
and—if the lesion demonstrates suspicious features—
mammography is recommended to evaluate for suspi-
cious calcifications that extend further than the lesion
visible on US. Furthermore, with adequate abdominal
shielding, bilateral mammography in two planes delivers
a dose of <0.06 Gy to the fetus and, thus, presents a neg-
ligible risk.31 56 69 Initially, one mediolateral oblique
view should be acquired. In case of suspicious findings
in addition to those discovered on US, craniocaudal as
well as mediolateral oblique views of both breasts are
needed to evaluate the patient for multicentric and
bilateral disease.30 56 Owing to the necessity for
gadolinium-based contrast agent and its inherent risks to
the fetus, breast MRI cannot be recommended during
pregnancy, and it should only be used with the utmost
caution if US and mammography are deemed inad-
equate, and if essential diagnostic information is
expected.
Along with the lungs, the bones and liver are the most
common sites of metastatic spread. Chest X-ray or CT,
US of the liver and MRI, without contrast agent, for the
detection of osseous lesions are recommended for
staging in locally advanced disease or in case of symp-
toms suggestive of distant metastases.1 If the risk for
distant metastases is low, imaging for distant disease
should be postponed until after pregnancy, if performed
at all.30
Cervical cancer
Abdominopelvic staging is usually performed by MRI
without contrast agent using mainly T2-weighted
sequences that provide information about local extent
(including hydronephrosis as a sign of parametric inva-
sion), lymphatic spread and distant metastases to the
abdomen.56 70 For the evaluation of distant metastases to
the lungs and bones, the same guidelines as those for
breast cancer should be followed.
Haematological malignancies
Hodgkin’s disease is a more frequent occurrence during
pregnancy than non-Hodgkin’s lymphoma, due to a
peak in incidence in young adults. An unusual presenta-
tion of a haematological malignancy that is associated
with pregnancy is bilateral lymphoma of the breast.56 71
Bilateral breast involvement with acute lymphoblastic
leukaemia has also been described.72
In newly diagnosed lymphoma in the non-pregnant
patient, PET-CT of the neck, chest, abdomen and pelvis
is recommended, but this hybrid imaging modality is
generally not recommended during pregnancy.73 74
Instead, US of the neck, abdomen and pelvis, as well as
MRI without contrast of the neck, chest and abdomen,
are preferable. CT of the chest may be added if MRI is
insufficient for the evaluation of pulmonary parenchy-
mal disease. If available, PET/MRI might be a reason-
able option, offering high soft tissue contrast and
functional information.54 In the diagnosis and staging of
leukaemia, a disease conceptualised as a disseminated
malignancy of the haematopoietic system, there is no
role for imaging-based staging as in other malignan-
cies.75 Whenever imaging is warranted, non-ionising
imaging modalities are preferred over X-rays and CT, as
a general rule, if a high degree of diagnostic accuracy
can be obtained with these modalities.
Melanoma
The indication for staging examinations in melanoma
depends on the depth of invasion of the primary skin
lesion and on regional lymph node status or clinically
evident signs of distant metastases. Routine radiological
staging is recommended in patients with stage III and IV
disease only.76 In patients with a low risk for distant
metastases, if imaging is requested at all, chest X-ray and
US of the liver and the regional lymph nodes may be
used. If the melanoma is located on the lower extrem-
ities or lower body, MRI may be warranted to evaluate
for pelvic lymphadenopathy.56 Evaluation for pulmonary
Table 3 Incidence rates of the most frequently diagnosed
malignancies during pregnancies
Incidence of malignant tumours per pregnancies or
deliveries
Tumour type Incidence
Breast cancer 1:3000–10 000
Cervical cancer 1:2000–10 000
Hodgkin’s lymphoma 1:1000–6000
Melanoma 2–5:100 000
Leukaemia 1:75 000–100 000
Ovarian cancer 4–8:100 000
Colorectal cancer 1:13 000
Thyroid cancer 14:100 000
Brain and spine 3.6:1 000 000
Gestational trophoblastic tumour 1:20 000–1:160 000
Modified from references1 56 83 and84.
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or brain metastatic disease follows the aforementioned
recommendations.
Ovarian cancer
US is usually the first—and often the only—imaging
modality to evaluate ovarian masses. In case of suspi-
cious features, MRI without contrast agent may be
helpful to further characterise the lesion and to evaluate
the abdominal cavity for any sign of malignancy or
metastases. In the presence of suspicious features on US
or MRI, surgical evaluation is usually required.56
Thyroid cancer
US is usually the first-line imaging modality to evaluate
the thyroid and cervical lymph nodes. In case of suspi-
cious findings, histological diagnosis rather than thyroid
scintigraphy may be attempted.56 77 Especially in cases
of poorly differentiated aggressive types of thyroid
cancer, chest imaging may be warranted, because the
lungs are the most common sites of distant metastases.
Therefore, native CT or MRI of the chest may be per-
formed, with CT having the highest sensitivity for small
pulmonary nodules, which are often seen in thyroid
cancer.58–61
Malignant tumours of the brain and spine
MRI is the imaging modality of choice in suspected
primary tumours of the brain and spine. In the charac-
terisation of a central nervous system tumour,
contrast-enhanced MRI and perfusion MRI play essential
roles and should not be withheld if the information
gained is expected to affect treatment.56 Advanced MRI
sequences, such as arterial spin labelling, which may
identify malignant gliomas based on hyperperfusion
without the use of gadolinium-based contrast agents,
may obviate the need for contrast administration.78
Gestational trophoblastic tumour
Gestational trophoblastic tumours arise as a direct conse-
quence of pregnancy. They comprise hydatiform moles,
placental site trophoblastic tumours and choriocarcin-
oma, with choriocarcinoma being the most malignant
form.56 79 For the assessment of local tumour extent, US
and MRI without contrast can be used. MRI allows
assessment of the entire abdomen for metastatic
lesions.75 Pulmonary metastases are a frequent occur-
rence and should be evaluated using chest radiography
or chest CT.80
COUNSELLING AND INFORMED CONSENT
The pregnant patient, probably even more than the
non-pregnant patient, will have doubts about the risks
posed by diagnostic imaging. The objective of informed
consent is to address the patient’s questions, and to
provide information about the possible risks and bene-
fits of diagnostic imaging.4 9 19 The oncologist, together
with the radiologist, is encouraged to make every effort
to explain to the patient—in a way that the patient is
able to understand and follow—the reasons for imaging,
the imaging procedures, and the risks and benefits of
the imaging method chosen. Although some imaging
methods may increase the risks of teratogenesis or car-
cinogenesis, the patient should be informed about the
comparatively small absolute risks even after completing
imaging.4 9 19 It is also essential that the patient under-
stands the potential benefits of the planned examination
and knows why she might need to be exposed to radi-
ation or other imaging. The referring clinician may also
be encouraged to help explain to the patient that
imaging is required in order to obtain necessary diag-
nostic information. Written, informed consent should be
obtained from all patients.4
CONCLUSION
Diagnostic imaging for staging pregnant patients with
cancer is a challenging task that must be addressed by a
multidisciplinary team of physicians. As a first step, the
team has to consider the possible benefits imaging may
provide the individual patient for overcoming her
disease. The multidisciplinary team must make the most
useful choice of imaging modalities, to obtain informa-
tion needed to offer the patient the most effective treat-
ment for the disease stage. The radiologist is a crucial
player in this process, as he or she must guide the
choice of imaging modalities in such a way that will
accurately answer the clinicians’ questions, keeping in
mind that not only the patient, but also the unborn
child, must be protected from excess radiation and risk.
Finally, the team of physicians should involve and
counsel the patient in such a way that she does not have
to fear harm to herself or the fetus from single, well-
planned imaging studies.
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